0000000000598341

AUTHOR

Lars P. Bechmann

0000-0003-3487-9810

showing 3 related works from this author

Onset of heart failure determines the hepatic cell death pattern.

2011

Background and rationale. Acute and chronic heart failure (HF) may affect the liver, but the underlying mechanisms that lead to progressive liver damage are poorly understood. The hepatic cytokeratin-18 (CK18) epitopes M65 and M30 have been reported to distinguish between overall (necrotic) and apoptotic cell death, respectively. We aimed to evaluate the predominant hepatic cell death pattern in acute vs. chronic heart failure and examined if these assays predict the course of the disease. Main results. In a prospective study comprising 21 patients with acute HF (AHF) and 18 patients with chronic HF (CHF) serum levels of M65 and M30 were assessed. Compared with CHF, M65 levels were signific…

Cell deathMalemedicine.medical_specialtyProgrammed cell deathMedizinM65Specialties of internal medicineApoptosisLiver injuryEpitopesPredictive Value of TestsInternal medicinemedicineHumansProspective StudiesProspective cohort studySurvival analysisHeart FailureLiver injuryKeratin-18HepatologyCytokeratin 18business.industryM30Liver DiseasesGeneral MedicineMiddle AgedPrognosismedicine.diseaseSurvival AnalysisRC581-951LiverApoptosisPredictive value of testsHeart failureAcute DiseaseChronic DiseaseHepatic stellate cellCardiologyFemalebusinessBiomarkers
researchProduct

The GALAD Score as Potential Screening Test for Hepatocellular Carcinoma in Nonalcoholic Steatohepatitis: An International Multicenter Study

2019

The prevalence of nonalcoholic steatohepatitis (NASH) is rising rapidly and is currently the most common chronic liver disease in Western populations. Hepatocellular carcinoma (HCC) is a major complication of NASH and the current performance of screening approaches based on ultrasound shows limitations. To facilitate earlier diagnosis, this international multicenter study, with eight German and one Japanese center participating, tests the potential benefit of applying the biomarkers AFP, AFP-L3, DCP and related scores for HCC screening in NASH patients. In the retrospective German cohort, 126 NASH patients with newly diagnosed HCC and 231 NASH control patients without HCC were enrolled. In …

medicine.medical_specialtyeducation.field_of_studybusiness.industryPopulationInstitutional review boardmedicine.diseaseChronic liver diseasedigestive system diseasesHelsinki declarationMulticenter studyInternal medicineHepatocellular carcinomaCohortMedicineAFP-L3businesseducationneoplasmsSSRN Electronic Journal
researchProduct

GALAD Score Detects Early Hepatocellular Carcinoma in an International Cohort of Patients With Nonalcoholic Steatohepatitis

2020

Background & Aims The prevalence of nonalcoholic steatohepatitis (NASH) associated hepatocellular carcinoma (HCC) is increasing. However, strategies for detection of early-stage HCC in patients with NASH have limitations. We assessed the ability of the GALAD score, which determines risk of HCC based on patient sex; age; and serum levels of α-fetoprotein (AFP), AFP isoform L3 (AFP-L3), and des-gamma-carboxy prothrombin (DCP), to detect HCC in patients with NASH. Methods We performed a case-control study of 125 patients with HCC (20% within Milan Criteria) and 231 patients without HCC (NASH controls) from 8 centers in Germany. We compared the performance of serum AFP, AFP-L3, or DCP vs GALAD …

medicine.medical_specialtyCirrhosisCarcinoma HepatocellularMedizinPilot ProjectsMilan criteriaGastroenterologySensitivity and SpecificityCohort Studies03 medical and health sciences0302 clinical medicineNon-alcoholic Fatty Liver DiseaseInternal medicinemedicineBiomarkers TumorHumansProtein PrecursorsneoplasmsHepatologyReceiver operating characteristicbusiness.industryLiver NeoplasmsGastroenterologyArea under the curvemedicine.diseasedigestive system diseasesROC Curve030220 oncology & carcinogenesisHepatocellular carcinomaCase-Control StudiesCohort030211 gastroenterology & hepatologyProthrombinalpha-FetoproteinsbusinessLiver cancerBiomarkersCohort study
researchProduct